Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


Get your full text copy in PDF

Treatment with Recombinant Factor XIII (Tretten) in a Pregnant Woman with Factor XIII Deficiency

Nizar Abdel-Samad

(Department of Internal Medicine, The Moncton Hospital, Moncton, NB, Canada)

Am J Case Rep 2017; 18:436-439

DOI: 10.12659/AJCR.901502

BACKGROUND: Factor XIII deficiency is associated with recurrent miscarriages in women.
CASE REPORT: In this report, we present a patient with factor XIII deficiency and some comorbidities who had had previous miscarriages. She began treatment with factor XIII subunit A (XIII-A) replacement treatment Recombinant factor XIII (Tretten) at a dose of 2500 units monthly and was able, for the first time, to carry a pregnancy almost to term. Although she experienced some obstetrical complications, she delivered a healthy baby. To the best of our knowledge, this is the first report of the use of Tretten during pregnancy.
CONCLUSIONS: Tretten, which is not indicated in pregnancy, offered a safe, effective treatment for miscarriages secondary to factor XIII-A deficiency in our patient. Further research is required to confirm this finding.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree